Open AccessP1253: MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRÖM'S MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B‐CELL TARGETED THERAPIES
Author(s) -
Monticelli H.,
Kruitwagen T.,
Tardelli M.,
Rebelo T.,
Maierhofer B.,
MaierMunsa S.,
Zmajkovicova K.,
Taveras A. G.,
Nguyen C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847876.35483.fd
Subject(s) - waldenstrom macroglobulinemia , ibrutinib , cancer research , bone marrow , cxcr4 , stromal cell , bruton's tyrosine kinase , progenitor cell , b cell , haematopoiesis , lymphoplasmacytic lymphoma , immunology , medicine , chemistry , stem cell , leukemia , biology , chemokine , chronic lymphocytic leukemia , microbiology and biotechnology , receptor , antibody , lymphoma , inflammation , tyrosine kinase